EGFR and non-small cell lung carcinoma: Another phase III study showed that osimertinib had significantly greater efficacy than chemotherapy (platinum therapy plus pemetrexed) in patients with EGFR T790M-mutated advanced NSCLC who had progressed after first-line therapy with EGFR TKIs, as PFS was 8.5 months among patients with metastases to the central nervous system receiving osimertinib vs. 4.2 months receiving platinum therapy plus pemetrexed [163].